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Abstract Substituted morpholin-2-one derivatives were readily obtained in two 
steps staring from commercially available N-protected amino acids. In a metal-
free and practical method, a catalytic amount of trifluoromethanesulfonic acid 
was sufficient to generate morpholinones under mild reaction conditions in an 
intramolecular hydroamination reaction in good to excellent yields. 
Key words amino acids, cyclization, hydroamination, morpholinone, 
trifluoromethanesulfonic acid 
 
Morpholinone derivatives occur frequently as a central unit in 
drug discovery and medicinal chemistry.1 
Substituted morpholin-2-ones are not only important derivatives 
in pharmaceutical industry with recent examples including anti-
fungal agents2 and compounds with potential in cancer 
chemotheraphy,3 they can also be versatile precursors for ring-
opening reactions. For example, the organocatalytic ring opening 
polymerization of N-acyl morpholin-2-ones can generate 
functionalized poly(aminoesters) with N-acylated amines,4 while 
the alcoholysis of optically active morpholin-2-ones yielded 
hydroxy amides in a stereoselective way.5 
Morpholin-2-ones are generally prepared by metal-catalyzed 
cyclizations. Palladium,6 rhodium7 and gold8 catalysts have been 
employed as major strategies for generating morpholin-2-one 
derivatives. N-Substituted morpholin-2-ones were also prepared 
by alternative methods.9 However, we are not aware of any 
report describing an acid-catalyzed synthesis of substituted 
morpholinones, probably due to the acid-sensitivity of N,O-
morpholinones. Moreover, there are only a few reports on the 
syntheses 5,5-disubstituted morpholinone derivatives, although 
they are important pharmacophores in medicinal chemistry.10 
We describe herein a simple and efficient two-step method to 
access substituted morpholin-2-ones starting from commercially 
available N-protected amino acids as building blocks under 
metal-free conditions. 
In continuation to access small bioactive molecules containing 
oxygen and nitrogen heteroatoms through cyclizations,11 we 
selected morpholin-2-ones as challenging acid sensitive 
heterocyclic frameworks. For initial investigations, commercially 
available Fmoc-L-alanine was reacted with methyl allyl chloride 
and potassium carbonate to yield the methylallyl ester 1 in 95% 
yield.  
Table 1 Screening of various acidic catalysts for the synthesis of 3,5,5-
trimethyl morpholin-2-one 2. 
 
Entry Reagent Time 
(h) 
Tempera
ture (°C) 
Yield 
(%) 
1 Amberlyst-15[a] 24 20 
no 
reaction 
2 Nafion® NR50[a] 24 2 
no 
reaction 
3 
Silica supported 
tungstic acid 
20 20 
no 
reaction 
4 SiO2[a] 20 20 
no 
reaction 
5 H2SO4 (0.25 eq) 1 20 85% 
6 TfOH (0.2 eq)[b] 1 0 84% 
7 TfOH (0.2 eq)[c] 0.33 0 93% 
[a] 200 mg / mmol. [b] Added neat. [c] Added as 0.1 M solution in 
CH2Cl2. 
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The N-protected allyl-ester 1 was subjected to different acidic 
catalysts as shown in Table 1. While ion exchange resins (entries 
1 and 2) and silica-supported tungstic acid (entry 3) were 
completely unreactive towards 1, catalytic amounts of sulfuric or 
trifluoromethanesulfonic acid led to good conversions. High 
yields (93%) of 3,5,5-trimethyl morpholin-2-one 2 were 
obtained with 0.2 equivalents of trifluoromethanesulfonic acid at 
0 °C for 20 min (entry 6). 
We then further studied the scope of the cyclization reaction with 
different protection groups on the nitrogen of phenylalanine 
esters 3. As shown in Scheme 1, the Fmoc protected derivative 3a 
cyclized as expected to the morpholin-2-one derivative 4a in 
92% yield. Another group such as the benzyloxycarbonyl (Cbz) 
protecting group were less efficient (4b formed in 75% yield, 
while the substrate with a methyloxycarbonyl group 3c did not 
form any cyclized product. Interestingly, in this case only a 
double bond isomerization to compound 5 was observed under 
identical reaction conditions. As expected, allyl ester 6, either 
protected as sulfonamide or as Fmoc, required a much longer 
exposure of one equivalent of trifluoromethanesulfonic acid in 
toluene at 65 °C for two hours to yield a 1:1 cis/trans mixture of 
inseparable diastereomers of both products, 7a and 7b. Allyl 
ester 6b did neither react under similar conditions with 
Amberlyst-15 as catalyst nor at lower temperatures (40 °C). 
 
Scheme 1 Synthesis of morpholin-2-one derivatives from phenylalanine 
precursors. 
Other N-protected amino esters were synthesized according to a 
literature procedure12 and then subjected to the reaction 
conditions shown in Table 1, Entry 7. 
The N-Fmoc glycine ester 8a gave the desired morpholinone 9a 
in 87% yield after one-hour reaction time with 0.4 equivalents of 
trifluoromethanesulfonic acid. Valine derivative 8b cyclized 
completely after 10 minutes to give 3-isopropyl-5,5-dimethyl 
morpholinone 9b in quantitative yield. Surprisingly, N-Fmoc 
methionine 8c was stable under the acidic conditions to give 
morpholinone 9c in 90% yield. Compound 9d did not cyclize 
under the reaction conditions but isomerized to compound 10. 
Further investigations with alanine ester were carried out with 
deuterated sulfuric acid (solution 96-98 wt. % in D2O). While 0.2 
equivalents D2SO4 gave only 17% of the product 11 (determined 
by 1H NMR), one equivalent of D2SO4 was needed to complete the 
cyclization and 11 was obtained in 86% yield. 
 
Scheme 2 Synthesis of morpholin-2-one derivatives from other N-Fmoc 
protected amino acids. 
In conclusion, we describe an efficient, general and transition-
metal free methodology for the synthesis of substituted 
morpholin-2-ones using an intramolecular hydroamination 
reaction of allyl amino acid derivatives mediated by catalytic 
amounts of trifluoromethanesulfonic acid in good to excellent 
yields. 
 
The experimental section has no title; please leave this line here. 
All reactions were carried out in oven−dried glassware under an 
atmosphere of nitrogen/argon using anhydrous solvents. All commercial 
reagents were used as received. Proton nuclear magnetic resonance 1H 
NMR spectra were recorded at 300, 400 and 500 MHz. Chemical shifts were recorded in parts per million ȋppm, δȌ relative to tetramethyl silane ȋδ Ͳ.ͲͲȌ. 1H NMR splitting patterns are designated as singlet (s), doublet 
(d), doublet of doublet (dd), triplet (t), quartet (q), multiplet (m). Carbon 
nuclear magnetic resonance 13C NMR spectra were recorded at 100 
MHz/125 MHz. Mass spectra (MS) were obtained using ESI mass 
spectrometers. IR spectra were recorded as neat for liquid and in KBr for 
solids. Melting points were determined using a hot stage apparatus and 
were uncorrected. Optical rotations were measured using a 10.0 mL cell with a ͳ.Ͳ dm path length and are reported as [α] ȋc in g per ͳͲͲ mL, 
solvent) at 20 °C. 
Procedures 
Synthesis of N-Fmoc protected allyl esters: 
To the N-protected amino-acid (4.0 mmol) in dry DMF (20 mL) 3-chloro-
2-methyl-1-propene (450 mg, 5.0 mmol) was added at room temperature. 
Next, anhydrous K2CO3 (1.0 g) was added in one portion. The reaction was 
stirred for 18 hours at room temperature. Once the TLC indicated 
consumption of the starting material, the mixture was diluted with EtOAc 
(100 mL) and the organic phase was washed by HCl solution (2.0 M), 
brine, and dried over anhydrous MgSO4. The solvent removed under 
reduced pressure to give the crude residue. Flash silica gel 
chromatography (CH2Cl2/hexane 9:1) provided the allyl ester. 
Acid-catalyzed cyclization: 
The ester (1.00 mmol) was taken up in anhydrous CH2Cl2 (20 mL) and the 
solution was cooled to 0 °C. Trifluoromethanesulfonic acid (32 mg, 0.2 
mmol) was then added. The completed reaction was quenched with sat. 
aq. potassium carbonate (5 mL). The aqueous layer was extracted with 
dichloromethane (2 x 10 mL) and the combined organic extracts were 
dried, filtered and evaporated to yield the product. 
 
2-Methylallyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alaninate (1) 
Synthesized according to the general procedure, Fmoc-Ala-OH (1.56 g, 5.0 
mmol) gave the allyl ester as white solid, m.p. 116 – 118 °C (1.74 g, 95%). [α]D20 –10 (c 0.2, CH2Cl2). 
IR (neat): 2922, 2852, 1722, 1707, 1531, 1500, 1250 1040 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.67 (d, J = 7.5 Hz, 2H), 7.51 (dd, J = 7.1, 3.8 
Hz, 2H), 7.34 – 7.27 (m, 2H), 7.22 (dd, J = 7.4, 1.1 Hz, 2H), 5.33 (d, J = 7.5 
Hz, 1H), 4.90 (s, 1H), 4.86 (s, 1H), 4.49 (q, J = 13.1 Hz, 1H), 4.37 (dd, J = 
14.4, 7.1 Hz, 1H), 4.29 (dd, J = 14.3, 8.8 Hz, 2H), 4.13 (t, J = 7.0 Hz, 2H), 1.67 
(s, 3H), 1.38 (d, J = 7.2 Hz, 2H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 172.8, 155.6, 143.9, 141.3, 139.4, 127.7, 
127.1, 125.1, 119.9, 113.5, 68.6, 67.0, 49.7, 47.2, 19.4, 18.8. ppm 
HRMS (EI) m/z calcd for C22H24NO4 [M]+ = 366.1705; found: 366.1693. 
 
(S)-(9H-Fluoren-9-yl)methyl 3,5,5-trimethyl-2-oxomorpholine-4-
carboxylate (2) 
According to the general procedure, the ester 1 (365 mg, 1.0 mmol) and 
triflic acid (32 mg, 0.2 mmol) (20 min, 0 °C) gave the product as yellow oil 
(341 mg, 93%). [α]D20 –2.5 (c 1.0, CH2Cl2). 
According to the general procedure, the ester 1 (365 mg, 1.0 mmol) and 
sulfuric acid (25 mg, 0.25 mmol) (60 min, rt) gave the product as yellow 
oil (313 mg, 85%). 
IR (neat): 2830, 2802, 1719, 1697, 1108, 1090, 1002 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.62 (d, J = 7.5 Hz, 2H), 7.47 – 7.42 (m, 2H), 
7.25 (t, J = 7.5 Hz, 2H), 7.16 (dd, J = 7.5, 1.0 Hz, 2H), 4.33 – 4.27 (m, 1H), 
4.25 (d, J = 6.9 Hz, 2H), 4.07 (t, J = 6.9 Hz, 1H), 3.94 – 3.86 (m, 2H), 1.32 (d, 
J = 7.1 Hz, 3H), 1.10 (s, 6H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 173.3, 155.7, 143.8, 141.3, 127.8, 127.1, 
125.1, 120.0, 72.7, 69.8, 67.1, 50.1, 47.1, 26.1, 18.4 ppm. 
HRMS (EI) m/z calcd for C22H24NO4 [M]+ = 366.1705; found: 366.1698. 
 
2-Methylallyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenyl-
alaninate (3a) 
According to the general procedure, Fmoc-Phe-OH (1.94 g, 5.0 mmol) gave 
the allyl ester as white solid, m.p. 125 – 128 °C (2.00 g, 91%). [α]D20 +31.4 
(c 0.86, CH2Cl2). 
IR (neat): 3228, 2846, 1738, 1502, 1248, 1014 cm–1.  
1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 7.5 Hz, 2H), 7.62 – 7.55 (m, 2H), 
7.43 (t, J = 7.5 Hz, 2H), 7.35 – 7.28 (m, 2H), 7.14 (d, J = 6.7 Hz, 2H), 5.29 (d, 
J = 8.3 Hz, 1H), 4.99 (d, J = 8.4 Hz, 2H), 4.75 (dd, J = 14.1, 6.0 Hz, 1H), 4.57 
(q, J = 12.9 Hz, 2H), 4.46 (dd, J = 10.6, 7.2 Hz, 1H), 4.37 (dd, J = 10.6, 7.0 Hz, 
1H), 4.24 (t, J = 7.1 Hz, 1H), 3.27 – 3.22 (m, 2H), 1.75 (s, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 171.3, 155.6, 143.9, 141.4, 139.4, 128.0, 
127.8, 127.7, 127.6, 127.1, 125.1, 120.0, 113.7, 68.8, 67.0, 55.0, 47.0, 38.4, 
19.4 ppm. 
HRMS (CI) m/z calcd for C28H27NO4Na [M]+ = 464.1838; found: 464.1840. 
 
2-Methylallyl ((benzyloxy)carbonyl)-L-phenylalaninate (3b) 
According to the general procedure, Cbz-Phe-OH (1.50 g, 5.0 mmol) gave 
the allyl ester as colorless oil (1.30 g, 73%). [α]D20 +28.1 (c 0.64, CH2Cl2). 
IR (neat): 3334, 1724, 1261, 1203, 1187 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.39 – 7.33 (m, 5H), 7.29 – 7.23 (m, 3H), 
7.13 (dt, J = 11.6, 6.0 Hz, 2H), 5.26 (d, J = 8.1 Hz, 1H), 5.12 (d, J = 1.5 Hz, 
2H), 4.98 (d, J = 7.5 Hz, 2H), 4.73 (dt, J = 8.2, 6.0 Hz, 2H), 4.55 (q, J = 13.0 
Hz, 2H), 3.26 – 3.20 (m, 2H), 1.73 (s, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 171.3, 155.6, 139.2, 136.2, 135.7, 129.3, 
128.7, 128.2, 128.1, 127.8, 127.2, 127.1, 113.9, 68.8, 67.0, 54.9, 38.3, 19.5 
ppm. 
HRMS (CI) m/z calcd for C21H23NO4Na [M]+ = 376.1525; found: 376.1529. 
 
2-Methylallyl (methoxycarbonyl)-L-phenylalaninate (3c) 
According to the general procedure, Moc-Phe-OH (1.12 g, 5.0 mmol) gave 
the allyl ester 3c as colorless oil (1.00 g, 72%). [α]D20 +3.33 (c 0.24, 
CH2Cl2). 
IR (neat): 2356, 2923, 2811, 1736, 1711, 1305, 1054 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.32 – 7.27 (m, 3H), 7.15 (dd, J = 5.1, 2.8 Hz, 
2H), 5.17 (d, J = 7.7 Hz, 1H), 4.99 – 4.94 (m, 2H), 4.74 – 4.65 (m, 1H), 4.53 
(t, J = 4.7 Hz, 2H), 3.67 (s, 3H), 3.14 (t, J = 5.3 Hz, 2H), 1.72 (s, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 171.3, 135.7, 129.3, 128.6, 127.2, 113.9, 
19.6 ppm. 
HRMS (EI) m/z calcd for C21H22NO4 [M]+ = 277.1314; found: 277.1305. 
 
(S)-(9H-Fluoren-9-yl)methyl 3-benzyl-5,5-dimethyl-2-oxomorpho-
line-4-carboxylate (4a) 
According to the general procedure, ester 3a (220 mg, 0.5 mmol) and 
triflic acid (32 mg, 0.2 mmol, 0.4eq) gave the product as colourless oil (202 
mg, 92%). [α]D20 –16.7 (c 0.6, CH2Cl2). 
IR (neat): 2824, 1729, 1411, 1278, 1027 cm–1. 
1H NMR (400 MHz, CDCl3): δ= 7.68 (d, J = 7.5 Hz, 2H), 7.47 (dd, J = 6.9, 4.5 
Hz, 2H), 7.35 – 7.27 (m, 2H), 7.27 – 7.16 (m, 5H), 4.61 (dd, J = 14.2, 6.7 Hz, 
1H), 4.42 – 4.32 (m, 2H), 4.27 (dd, J = 10.6, 6.9 Hz, 2H), 4.12 (t, J = 6.9 Hz, 
1H), 3.89 (q, J = 11.0 Hz, 2H), 3.11 – 3.03 (m, 2H), 1.08 (t, J = 8.0 Hz, 6H) 
ppm. 
13C NMR (126 MHz, CDCl3): δ = 170.6, 154.9, 142.9, 140.3, 134.7, 128.2, 
127.7, 126.7, 126.3, 126.0, 123.9, 119.1, 72.2, 68.4, 65.9, 53.7, 46.3, 37.4, 
24.8 ppm. 
HRMS (CI) m/z calcd for C28H27NO4Na [M]+ = 464.1838; found: 464.1853. 
 
(S)-Benzyl 3-benzyl-5,5-dimethyl-2-oxomorpholine-4-carboxylate 
(4b) 
According to the general procedure, ester 4a (177 mg, 0.5 mmol) and 
triflic acid (32 mg, 0.2 mmol, 0.4eq) gave the product as colourless oil (132 
mg, 75%). [α]D20 +21.4 (c 1.4, CH2Cl2). 
IR (neat): 2968, 1704, 1184, 1109, 1022 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.24 – 7.10 (m, 7H), 7.06 – 6.99 (m, 3H), 
4.95 (app. s, 2H), 4.54 (dd, J = 14.3, 6.7 Hz, 1H), 3.87 – 3.74 (m, 2H), 2.98 – 
2.74 (m, 29H), 1.04 (s, 6H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 168.9, 155.5, 139.2, 130.7, 129.2, 74.6, 
73.0, 54.7, 41.6, 26.3, 22.3, 18.5 ppm. 
HRMS (CI) m/z calcd for C21H23NO4Na [M]+ = 376.1525; found: 376.1529. 
 
2-Methylprop-1-en-1-yl (methoxycarbonyl)-L-phenylalaninate (5) 
According to the general procedure, the ester 3c (139 mg, 0.5 mmol) and 
triflic acid (32 mg, 0.2 mmol) gave the product 5 as colourless oil (130 mg, 
94%). [α]D20 –5.56 (c 0.54, CH2Cl2). 
IR (neat): 2847, 1706, 1694, 1583, 1034 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.24 – 7.17 (m, 3H), 7.08 – 7.03 (m, 2H), 
6.74 (dd, J = 2.9, 1.4 Hz, 1H), 5.14 (d, J = 13.5 Hz, 1H), 4.65 (d, J = 6.2 Hz, 
1H), 4.50 – 4.39 (m, 1H), 3.59 (s, 3H), 3.07 (d, J = 5.9 Hz, 2H), 1.58 (d, J = 
0.9 Hz, 3H), 1.54 (s, 3H) ppm. 
HRMS (EI) m/z calcd for C21H22NO4 [M]+ = 277.1314; found: 277.1311. 
 
Allyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alaninate (6a) 
Fmoc-Ala-OH (1.87 g, 6 mmol) was dissolved in CH2Cl2 (50 mL) and cooled 
to 0 °C. Allylic alcohol (0.4 mL, 5.7 mmol) was added. The solution was cooled to −ͳͷ °C. A solution of DCC ȋͳ.ʹg, ͷ.͹ mmolȌ and DMAP ȋ͹Ͳ mg, Ͳ.͸ 
mmol) in CH2Cl2 (50 mL) was added and the reaction was stirred at room 
temperature for 20 h. The precipitated N,N-dicyclohexyl urea was filtered 
off and washed with CH2Cl2. The organic layer was washed with 1 M HCl 
(10 mL) and saturated NaHCO3 (10 mL) solution. The organic phase was 
dried over Na2SO4, filtered and the solvent was evaporated in vacuo. The 
crude product was purified by flash chromatography CH2Cl2/MeOH 
(10:0.2) to give the ester 6a as a colourless oil (1.76 g, 88%). [α]D20 –3.57 
(c 0.28, CH2Cl2). 
IR (neat): 3291, 2882, 2811, 1744, 1721, 1219, 1025 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.66 (d, J = 7.5 Hz, 2H), 7.50 (dd, J = 7.1, 3.5 
Hz, 2H), 7.30 (t, J = 7.2 Hz, 2H), 7.21 (td, J = 7.4, 1.1 Hz, 2H), 5.81 (ddd, J = 
22.7, 10.9, 5.7 Hz, 1H), 5.37 (d, J = 7.6 Hz, 1H), 5.23 (dd, J = 17.2, 1.2 Hz, 
1H), 5.15 (dd, J = 10.4, 1.2 Hz, 1H), 4.55 (d, J = 5.4 Hz, 2H), 4.40 – 4.23 (m, 
3H), 4.12 (t, J = 7.0 Hz, 1H), 1.35 (d, J = 7.2 Hz, 3H) ppm. 
13C NMR (126 MHz, CDCl3): δ = 155.7, 141.3, 131.58, 127.7, 127.1, 125.2, 
120.0, 118.8, 67.0, 66.0, 49.7, 47.2, 18.7 ppm. 
HRMS (EI) m/z calcd for C21H22NO4 [M]+ = 352.1549; found: 352.1547. 
 
Allyl tosyl-L-phenylalaninate (6b)13 
Ts-Phe-OH (1.9 g, 6 mmol) was dissolved in CH2Cl2 (50 mL) and cooled to 
0 °C. Allylic alcohol (0.4 mL, 5.7 mmol) was added. The solution was cooled to −ͳͷ °C. A solution of DCC ȋͳ.ʹg, ͷ.͹ mmol) and DMAP (70 mg, 0.6 
mmol) in CH2Cl2 (50 mL) was added and the reaction was stirred at room 
temperature for 20 h. The precipitated N,N-dicyclohexyl urea was filtered 
off and washed with CH2Cl2. The organic layer was washed with 1 M HCl 
(10 mL) and sat. aq. NaHCO3 (10 mL) solution. The organic phase was 
dried over Na2SO4, filtered and the solvent was evaporated in vacuo. The 
crude product was purified by flash chromatography CH2Cl2/MeOH (10 : 
0.2) to give the ester 6b as a colourless oil (1.44 g, 72%). [α]D20 –6,7 (c 0.3, 
CH2Cl2). 
IR (neat): 3252, 2990, 2824, 1734, 1584, 1219, 1017 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.52 (d, J = 8.3 Hz, 2H), 7.13 – 7.06 (m, 5H), 
7.01 – 6.94 (m, 2H), 5.55 (ddt, J = 17.6, 9.8, 5.9 Hz, 1H), 5.30 (d, J = 9.1 Hz, 
1H), 5.07 (t, J = 4.0 Hz, 1H), 5.05 – 4.99 (m, 1H), 4.22 (dd, J = 12.0, 7.2 Hz, 
2H), 4.10 (dt, J = 8.9, 6.2 Hz, 1H), 2.90 (d, J = 6.9 Hz, 2H), 2.27 (s, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 170.5, 143.6, 134.9, 130.9, 129.6, 128.6, 
66.1, 56.6, 39.5, 21.5 ppm. 
HRMS (CI) m/z calcd for C19H21NO4SNa [M]+ = 382.1089; found: 382.1080. 
 
(9H-Fluoren-9-yl)methyl (3S)-3,5-dimethyl-2-oxomorpholine-4-
carboxylate (7a) 
The ester 6a (176 mg, 0.5 mmol) and triflic acid (80 mg, 0.5 mmol) in dry 
toluene (20 mL) were heated for 2 h at 65 °C. The completed reaction was 
quenched with sat. aq. potassium carbonate (5 mL). The separated 
aqueous layer was extracted with toluene (2 x 10 mL) and the combined 
organic extracts were dried, filtered and evaporated to yield the product 
7a (126 mg, 72%) as a colourless oil 1:1 mixture of diastereoisomers, 
which could not be separated. 
IR (neat): 2834, 2800, 1714, 1698, 1466, 1305 cm–1. 
1H NMR (500 MHz, CDCl3): δ = 7.70 (dd, J = 7.5, 3.8 Hz, 2H), 7.52 (dd, J = 
14.3, 7.6 Hz, 2H), 7.33 (dt, J = 12.7, 6.5 Hz, 2H), 7.10 – 7.06 (m, 1H), 7.03 – 
7.00 (m, 1H), 4.49 – 4.43 (m, 1H), 4.43 – 4.37 (m, 1H), 4.36 – 4.30 (m, 2H), 
4.18 – 4.14 (m, 2H), 4.09 (d, J = 5.9 Hz, 1H), 3.75 (dd, J = 7.2, 4.3 Hz, 1H), 
1.29 – 1.24 (m, 3H), 0.87 – 0.81 (m, 3H) ppm. 
13C NMR (126 MHz, CDCl3): δ = 141.3, 129.2, 127.8, 127.2, 127.0, 124.9, 
120.1, 119.7, 49.7, 28.7, 18.6, 12.8 ppm. 
HRMS (EI) m/z calcd for C21H22NO4 [M]+ = 352.1549; found: 352.1546. 
 
(3S)-3-Benzyl-5-methyl-4-tosylmorpholin-2-one (7b) 
The ester 6b (180 mg, 0.5 mmol) and triflic acid (80 mg, 0.5 mmol) in dry 
toluene (20 mL) were heated for 2 h at 65 °C. The completed reaction was 
quenched with sat. aq. potassium carbonate (5 mL). The separated 
aqueous layer was extracted with toluene (2 x 10 mL) and the combined 
organic extracts were dried, filtered and evaporated to yield the product 
7b (154 mg, 86%) as a yellow oil as a 1:1 mixture of diastereomers, which 
could not be separated. 
IR (neat): 2823, 2801, 1717, 1522, 1112, 1017 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.29 – 7.24 (m, 4H), 7.15 (t, J = 6.2 Hz, 5H), 
5.34 – 5.11 (m, 1H), 4.24 (d, J = 5.4 Hz, 1H), 3.98 (t, J = 7.5 Hz, 1H), 3.75 (t, 
J = 7.7 Hz, 1H), 3.14 (dd, J = 13.9, 5.2 Hz, 1H), 3.02 (dd, J = 14.0, 6.6 Hz, 1H), 
2.33 (s, 3H), 0.91 (d, J = 7.5 Hz, 3H) ppm. 
13C NMR (126 MHz, CDCl3): δ = 171.0, 143.6, 136.7, 134.8, 129.6, 128.6, 
127.2, 67.3, 56.5, 39.6, 21.7, 21.5, 10.2 ppm. 
HRMS (CI) m/z calcd for C19H21NO4SNa [M]+ = 382.1089; found: 382.1082. 
 
2-Methylallyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino) 
acetate (8a) 
Synthesized according to the general procedure, Fmoc-Gly-OH (1.19 g, 4.0 
mmol) gave the allyl ester 8a as white solid m.p. 109 – 111 °C (1.21 g, 
86%). 
IR (neat): 3327, 1734, 1686, 1543, 1320, 1170 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.68 (d, J = 7.5 Hz, 2H), 7.52 (d, J = 7.4 Hz, 
2H), 7.32 (dd, J = 7.5, 1.2 Hz, 2H), 7.23 (dd, J = 7.4, 1.2 Hz, 2H), 5.29 (t, J = 
5.3 Hz, 1H), 4.92 – 4.85 (m, 2H), 4.50 (s, 2H), 4.32 (d, J = 7.1 Hz, 2H), 4.15 
(t, J = 7.1 Hz, 1H), 3.96 (d, J = 5.6 Hz, 2H), 1.67 (s, 3H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 169.9, 156.3, 143.8 (2C), 141.3 (2C), 139.2, 
127.8 (2C), 127.0 (2C), 125.13 (2C), 120.0 (2C), 113.7, 68.7, 67.2, 47.1, 
42.8, 19.5 ppm. 
HRMS (EI) m/z calcd for C21H21NO4 [M]+ = 351.1471; found: 351.1476. 
 
(S)-2-Methylallyl2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-
3-methylbutanoate (8b) 
Synthesized according to the general procedure, Fmoc-Val-OH (1.36 g, 4.0 
mmol) gave the allyl ester 8b (1.33 g, 85%). [α]D20 –2.00 (c 0.5, CH2Cl2). 
IR (neat): 2978, 2834, 1702, 1697, 1176, 1043 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 7.3 Hz, 
2H), 7.43 (dd, J = 7.5, 4.3 Hz, 2H), 7.35 (dd, J = 7.3, 4.3 Hz, 2H), 5.30 (d, J = 
4.7 Hz, 1H), 5.04 (s, 1H), 4.99 (s, 1H), 4.60 – 4.53 (m, 2H), 4.43 (d, J = 6.7 
Hz, 2H), 4.39 (dd, J = 9.2, 4.7 Hz, 1H), 4.26 (t, J = 7.1 Hz, 1H), 2.32 – 2.18 
(m, 1H), 1.79 (s, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.94 (t, J = 6.0 Hz, 3H) ppm. 
13C NMR (126 MHz, CDCl3): δ = 171.9, 156.2, 143.9, 143.8, 141.3, 139.2, 
127.7, 127.0, 125.1, 119.9, 113.7, 68.6, 67.1, 59.1, 47.2, 31.4, 19.6, 19.1, 
17.5 ppm. 
HRMS (EI) m/z calcd for C24H27NO4 [M]+ = 393.1949; found: 393.1952. 
 
(S)-2-Methylallyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-
4-(methylthio)butanoate (8c) 
According to general procedure, Fmoc-Met-OH (1.49 g, 4.0 mmol) gave the 
allyl ester 8c as yellowish solid, m.p. 94 – 95 °C (1.30 g, 76%). [α]D20 +59.2 
(c 1.74, CH2Cl2). 
IR (neat): 3325, 2943, 1724, 1711, 1238, 1054 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 7.4 Hz, 2H), 7.62 (d, J = 7.2 Hz, 
2H), 7.43 (t, J = 7.4 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 5.46 (d, J = 7.7 Hz, 1H), 
5.02 (s, 1H), 4.99 (s, 1H), 4.61 – 4.54 (m, 3H), 4.44 (d, J = 6.6 Hz, 2H), 4.26 
(t, J = 6.8 Hz, 1H), 2.57 (t, J = 6.9 Hz, 2H), 2.28 – 2.16 (m, 1H), 2.13 (s, 3H), 
2.09 – 1.96 (m, 1H), 1.79 (s, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 171.6, 155.7, 143.7, 141.2, 139.0, 127.6, 
126.8, 125.1, 119.8, 113.6, 68.9, 66.9, 53.1, 47.0, 31.9, 29.8, 19.4, 15.4 ppm. 
HRMS (EI) m/z calcd for C24H27NO4S [M]+ = 425.1661; found: 425.1665. 
 2-Methylallyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-isoleucinate 
(8d) 
According to the general procedure, Fmoc-Ile-OH (1.41 g, 4.0 mmol) gave 
the allyl ester 8d as colorless oil (1.40 g, 86%). [α]D20 -6.8 (c 1.5, CH2Cl2). 
IR (neat): 3304, 2911, 2820, 1720, 1698, 1287, 1165 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.79 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.4 Hz, 
2H), 7.42 (t, J = 7.3 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 5.39 (d, J = 9.1 Hz, 1H), 
5.02 (d, J = 7.9 Hz, 1H), 4.98 (s, 1H), 4.66 – 4.53 (m, 2H), 4.45 – 4.38 (m, 
2H), 4.26 (t, J = 7.0 Hz, 1H), 1.99 – 1.94 (m, 1H), 1.79 (s, 3H), 1.54 – 1.39 
(m, 1H), 1.33 – 1.13 (m, 1H), 0.95 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 7.8 Hz, 3H) 
ppm. 
13C NMR (75 MHz, CDCl3): δ = 171.9, 156.2, 143.9, 141.3, 139.3), 127.7, 
127.1, 125.1, 120.0, 113.9, 68.6, 67.0, 58.5, 47.2, 38.1, 25.0, 19.6, 15.6, 11.7 
ppm. 
HRMS (CI) m/z calcd for C25H29NO4Na[M]+ = 430.1994; found: 430.1998. 
 
(9H-Fluoren-9-yl)methyl 5,5-dimethyl-2-oxomorpholine-4-carboxy-
late (9a) 
According to the general procedure, the ester 8a (176 mg, 0.5 mmol) and 
triflic acid (32 mg, 0.2 mmol) gave the product as colourless oil (153 mg, 
87%). 
IR (neat): 3348, 2974, 1707, 1701, 1522, 1448, 1274 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.65 (d, J = 7.5 Hz, 2H), 7.49 (d, J = 7.4 Hz, 
2H), 7.30 (dd, J = 10.9, 3.9 Hz, 2H), 7.24 – 7.16 (m, 2H), 4.35 – 4.25 (m, 2H), 
4.15 – 4.07 (m, 1H), 3.95 – 3.89 (m, 3H), 1.13 (s, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 170.2, 156.6, 143.8 (2C), 141.3 (2C), 127.8 
(2C), 127.1 (2C), 125.1 (2C), 120.1 (2C), 72.6, 69.7, 67.3, 47.1, 42.8, 26.1 
(2C) ppm. 
HRMS (EI) m/z calcd for C21H21NO4 [M]+ = 351.1471; found: 351.1465. 
 
(S)-(9H-Fluoren-9-yl)methyl-3-isopropyl-5,5-dimethyl-2-oxomor-
pholine-4-carboxylate (9b) 
According to the general procedure, the ester 9a (394 mg, 1.0 mmol) and 
triflic acid (32 mg, 0.2 mmol) gave the product as colourless oil (385 mg, 
98%). [α]D20 –1.18 (c 0.34, CH2Cl2). 
IR (neat): 3228, 2924, 1717, 1677, 1432, 1198, 1034 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.66 (d, J = 7.5 Hz, 2H), 7.50 (d, J = 7.2 Hz, 
2H), 7.30 (dd, J = 7.2, 3.0 Hz, 2H), 7.21 (dd, J = 7.5, 3.0 Hz, 2H), 4.36 – 4.27 
(m, 2H), 4.27 – 4.20 (m, 1H), 4.12 (t, J = 6.9 Hz, 1H), 3.98 – 3.90 (m, 2H), 
2.22 – 2.10 (m, 1H), 1.15 (app. s, 6H), 0.89 (d, J = 8.3 Hz, 3H), 0.84 (d, J = 
6.8 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 172.2, 156.4, 143.8, 141.3, 127.8, 127.1, 
125.1, 120.0, 72.7, 69.7, 67.1, 59.3, 47.2, 31.2, 26.2, 19.1, 17.7 ppm. 
HRMS (EI) m/z calcd for C24H27NO4 [M]+ = 393.1940; found: 393.1949. 
 
(S)-(9H-Fluoren-9-yl)methyl 5,5-dimethyl-3-(2-(methylthio)ethyl)-
2-oxomorpholine-4-carboxylate (9c) 
According to the general procedure, ester 8c (213 mg, 0.5 mmol) and 
triflic acid (40 mg, 0.25 mmol) gave the product as yellow oil (192 mg, 
90%). [α]D20 -74.4 (c 1.64, CH2Cl2). 
IR (neat): 3325, 2943, 1724, 1711, 1238, 1054 cm–1. 
(1) (a) Nilsson, J. W.; Kvarnström, I.; Musil, D.; Nilsson, I.; Samulesson, 
B. J. Med. Chem. 2003, 46, 3985. (b) Wijtmans, R.; Vink, M. K. S.; 
Schoemaker, H. E.; Deilt, F. L.; Blaauw, R. H. Synthesis 2004, 641. (c) 
Couladours, E. A.; Moutsos, V. I.; Pitsinos, E. N. Tetrahedron Lett. 
2004, 45, 7779. (d) Shikre, B. A.; Deshmukh, A. R. A. S. Tetrahedron: 
1H NMR (400 MHz, CDCl3): δ= 7.67 (d, J = 7.4 Hz, 2H), 7.50 (d, J = 7.4 Hz, 
2H), 7.33 – 7.28 (m, 2H), 7.22 (dd, J = 7.4, 3.0, 2H), 4.44 (dd, J = 12.8, 7.7 
Hz, 1H), 4.36 – 4.30 (m, 2H), 4.13 (t, J = 6.8 Hz, 1H), 3.96 (s, 2H), 2.47 (t, J 
= 7.2 Hz, 2H), 2.17 – 2.04 (m, 1H), 2.01 (s, 3H), 1.96 – 1.91 (m, 1H), 1.15 (s, 
6H) ppm. 
13C NMR (101 MHz, CDCl3Ȍ δ ͳ͹ͳ.ͻ, ͳͷͷ.ͻ, ͳͶͶ.Ͳ, ͳͶͳ.ʹ, ͳʹ͹.ͺ, ͳʹ͹.ͳ, 
124.8, 119.9, 72.6, 69.8, 67.0, 53.6, 47.0, 31.5, 29.8, 26.1, 15.9 ppm. 
HRMS (EI) m/z calcd for C24H27NO4S [M]+ = 425.1661; found: 425.1667. 
 
2-Methylprop-1-en-1-yl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-
isoleucinate (10) 
According to the general procedure, ester 8d (204 mg, 0.5 mmol) and 
triflic acid (50 mg, 0.5 mmol) gave the product 10 as colourless oil (172 
mg, 84%). [α]D20 +2.5 (c 1.6, CH2Cl2). 
IR (neat): 3007, 2891, 2807, 1675, 1430, 1087 cm–1. 
1H NMR (300 MHz, CDCl3): δ = 7.70 (d, J = 7.4 Hz, 2H), 7.53 (d, J = 7.4 Hz, 
2H), 7.33 (t, J = 7.4 Hz, 2H), 7.25 (t, J = 7.4 Hz, 2H), 6.79 (s, 1H), 5.32 (d, J = 
7.8 Hz, 1H, 1H), 4.43 – 4.28 (m, 3H), 4.16 (t, J = 7.0 Hz, 1H), 1.99 – 1.77 (m, 
1H), 1.62 (s, 3H), 1.59 (d, J = 1.4 Hz, 3H), 1.47 – 1.32 (m, 1H), 1.26 – 1.14 
(m, 1H), 0.94 – 0.84 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 169.5, 156.1, 143.9, 141.3, 129.5, 127.7, 
127.1, 125.1, 120.0, 119.6, 67.1, 58.2, 47.2, 38.2, 25.1, 17.5, 15.5, 14.6, 11.7 
ppm. 
HRMS (CI) m/z calcd for C25H29NO4Na[M]+ = 430.1994; found: 430.1999. 
 
(9H-Fluoren-9-yl)methyl (3S)-3,5-dimethyl-5-(methyl-d)-2-oxomor-
pholine-4-carboxylate (11) 
According to the general procedure, ester 1 (183 mg, 0.5 mmol) and 
sulfuric acid-d2 solution 96-98 wt. % in D2O (55 mg, 0.5 mmol) (rt, 1 h) 
gave the product as yellow oil (153 mg, 86%).  
IR (neat): 2352, 2983, 1723, 1719, 1122, 1067 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 7.62 (d, J = 7.2 Hz, 2H), 7.41 – 7.22 (m, 2H), 
7.24 – 7.13 (m, 4H), 4.35 – 4.26 (m, 3H), 4.10 (t, J = 6.9 Hz, 1H), 3.93 (q, J = 
7.0 Hz, 2H), 1.35 (d, J = 7.0 Hz, 12H), 1.12 (d, J = 3.8 Hz, 2H), 1.12 (s, 3H) 
ppm. 
13C NMR (101 MHz, CDCl3): δ = 173.0, 155.8, 143.7, 141.2, 127.5, 127.0, 
125.0, 120.0, 72.7, 69.7, 67.1, 53.4, 49.8, 47.1, 26.0 (t, J = 6.9 Hz), 18.5, 17.5 
ppm. 
HRMS (EI) m/z calcd for C22H22DNO4 [M]+ = 366.1690; found: 366.1694. 
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(7) ȋaȌ Endo, Y.; Bäckvall, J.-E. Chem. Eur. J. 2011, 17, 12596. (b) Zhang, 
J.; Balaraman, E.; Leitus, G.; Milstein, D. Organometallics 2011, 30, 
5716. (c) Nicklaus, C. M.; Phua, P. H.; Buntara, T.; Noel, S.; Heeres, H. 
J.; de Vries, J. G. Adv. Synth. Catal. 2013, 355, 2839. 
(8) Mitsudome, T.; Noujima, A.; Mizugaki, T.; Jitsukawa, K.; Kaneda, K. 
Green Chem. 2009, 11, 793. 
(9) (a) Zhao, M. M.; McNamara, J. M.; Ho, G.-J.; Emerson, K. M.; Song, Z. 
J.; Tschaen, D. M.; Brands, K. M. J.; Dolling, U.-H.; Grabowski, E. J. J.; 
Reider, P. J.; Cottrell, I. F.; Ashwood, M. S.; Bishop, B. C. J. Org. Chem. 
2002, 67, 6743. (b) Kasima, C.; Harada, K. J. Chem. Soc., Perkin Trans. 
1 1988, 152. ( c ) Samanta, S.; Mal, A.; Halder, S.; Ghorai, M. K. 
Synthesis 2015, 47, 3776.  
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